May 03, 2019 7:05am EDT IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck’s Keytruda® in DLBCL
Apr 26, 2019 7:05am EDT IMV Inc. to Announce First Quarter 2019 Results and Host a Conference Call and Webcast on May 10, 2019
Apr 18, 2019 7:05am EDT IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors
Apr 16, 2019 9:31am EDT IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update
Apr 04, 2019 7:05am EDT IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference
Apr 03, 2019 8:00am EDT New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMV’s Immunotherapy Program
Mar 26, 2019 7:05am EDT Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer
Mar 21, 2019 5:05pm EDT IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs
Mar 18, 2019 7:05am EDT IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology
